First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration

Ophthalmology

Volumn 123, Issue 2, 2016, Pages 337-343

  Talks, James S ^a   Lotery, Andrew J ^b   Ghanchi, Faruque ^c   Sivaprasad, Sobha ^d   Johnston, Robert L ^e   Patel, Nishal ^f   McKibbin, Martin ^g   Bailey, Clare ^h   Mahmood, Sajjad ⁱ  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c BRADFORD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^e GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^g LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^h UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

ⁱ MANCHESTER ROYAL EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; AGE; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CLINICAL PRACTICE; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED KINGDOM; VISUAL ACUITY; VISUAL IMPAIRMENT; WET MACULAR DEGENERATION; ANTAGONISTS AND INHIBITORS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; ELECTRONIC HEALTH RECORD; FLUORESCENCE ANGIOGRAPHY; GREAT BRITAIN; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CLINICAL PROTOCOLS; ELECTRONIC HEALTH RECORDS; FEMALE; FLUORESCEIN ANGIOGRAPHY; GREAT BRITAIN; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84949035520     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.09.039     Document Type: Article

References (12)

1. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group The neovascular age-related macular degeneration database: multicenter study of 92 976 ranbizumab injections: report 1: visual acuity Ophthalmology 121 2014 1092 1101
2. S. Pushpoth, E. Sykakis, K. Merchant, and et al. Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration Br J Ophthalmol 96 2012 1469 1473
3. F. Holtz, R. Tadayoni, S. Beatty, and et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration Br J Ophthalmol 99 2015 220 226
4. M.C. Gillies, R.J. Walton, J.J. Arnold, and et al. Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort Ophthalmology 121 2014 676 681
5. D.M. Brown, P.K. Kaiser, M. Michels, et al. ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
6. P.J. Rosenfeld, D.M. Brown, J.S. Heier, et al. MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
7. D.F. Martin, M.G. Maguire, G.S. Ying, et al. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
8. IVAN Study Investigators Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
9. B.G. Busbee, A.C. Ho, D.M. Brown, et al. HARBOR study group Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 120 2013 1046 1056
10. C.D. Regillo, D.M. Brown, P. Abraham PIER Study Group Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1 Am J Ophthalmol 145 2008 239 248
11. J.S. Heier, D.M. Brown, V. Chong, et al. VIEW 1 and VIEW 2 Study Groups Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
12. J.J. Arnold, A. Campion, D. Barthelmes, et al. Fight Retinal Blindness Study Group Two-year outcomes of treat-and-extend intravitreal therapy for neovascular age-related macular degeneration Ophthalmology 122 2015 1212 1219